Skip to content

Multicenter Diagnostic Clinical Performance Study For Automated Detection of Diabetic Retinopathy

Multicenter Diagnostic Clinical Performance Study For Automated Detection of Diabetic Retinopathy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05471986
Enrollment
900
Registered
2022-07-25
Start date
2024-08-01
Completion date
2024-12-01
Last updated
2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Keywords

Diabetic Retinopathy, Artificial Intelligence, Deep Learning, Retinal images, Diabetic Macular Edema, Diabetic Eye Problems

Brief summary

This study is a retrospective study to assess the efficacy and accuracy of the EyeCheckup software in screening for diabetic retinopathy in healthcare settings.

Detailed description

This is a clinical diagnostic performance study for EyeCheckup with data obtained consecutively at multiple geographically different sites within the US population. These sites include all healthcare settings with a trained ophthalmic camera operator using non-mydriatic cameras that are compatible with EyeCheckup. Moreover, primary endpoints are devised that will be used to validate EyeCheckup to diagnose DR in the primary care and eye care settings. During this color fundus images representing either 4 wide field or 7 standard fields of view will be graded by a qualified professional for diabetic retinopathy according to ETDRS on DRSS scale. The human grading output will be compared with diagnosis generated for diabetic retinopathy by AI software. A comparison of both these grades will be used to determine sensitivity and specificity for the EyeCheckup software for screening for diabetic retinopathy.

Interventions

Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ

Sponsors

Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* A diagnosis of either diabetes type 1 or diabetes type 2 * 22 years of age or older * Patients Fundus images must include at least 1 macula centered and 1 optic disc nerve centered image * All the subjects must be sequentially photographed meaning no omissions of data between a certain time frame by the sites providing images to ensure consecutive selection * No history of any other retinal vascular disease, glaucoma, or another disease that may affect the appearance of the retina or optic disc (refractive error and ocular surface disease are allowed) Subject with image taken by color fundus photography that meets the following requirements: * The resolution of image is 1024×1024 pixels or higher * The ability to provide a 7 standard or 4 wide field of view * Must obtained from either Topcon NW400 or Cannon Model CR-2 AF or CR-2 Plus AF or Optomed Aurora Cameras along with the following data: their age, ethnicity and gender, patient ocular history as evaluated of verified by the clinical sites where data is obtained

Exclusion criteria

* No diagnosis of either diabetes type 1 or diabetes type 2 * The macula, optic nerve, or other part in the image of color fundus photography is unclear to determine the disease condition as judged by the certified ophthalmologist who is grading the images.

Design outcomes

Primary

MeasureTime frame
Sensitivity and Specificity of EyeCheckup to detect more than mild diabetic retinopathy1 visit (1 day)
Sensitivity and Specificity of EyeCheckup to detect vision-threatening diabetic retinopathy1 visit (1 day)

Secondary

MeasureTime frame
Positive Predictive Value1 visit (1 day)
Negative Predictive Value1 visit (1 day)

Contacts

Primary ContactRim Khazhin
trials@eye-checkup.com+905357666383

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026